Markowitz Wayne sold $13K of EW

The FTC proposed a settlement with Edwards Lifesciences and Genesis MedTech over alleged Hart-Scott-Rodino filing violations tied to Edwards’ July 2024 $115 million acquisition of JC Medical. The FTC says a $25 million Genesis non-voting share investment was additional deal consideration, making the combined value reportable. Edwards would pay $10 million and Genesis $2 million.

Edwards Lifesciences (NYSE: EW) reported Q2 revenue of $1.74B, up 14% year over year, and adjusted EPS of 78 cents, above expectations. Full-year sales guidance was raised to 10%-11%. TAVR sales grew 11% to $1.26B. CMS draft Medicare coverage could expand TAVR access, with a final decision expected in September.

Edwards Lifesciences (NYSE:EW) reported Q2 2026 net sales of $1.74B, up 13.6% YoY, and adjusted EPS of $0.78 vs $0.74 expected. TMTT revenue rose 47.3% YoY to $195.9M. The company raised full-year sales growth guidance to 10%–11% ($6.6B–$6.9B) and reaffirmed adjusted EPS of $2.95–$3.05.

Edwards Lifesciences said the FDA cleared its Ecliptis left atrial appendage exclusion system for use during cardiac surgery to help prevent clot formation in atrial fibrillation. The company plans a preliminary launch later this year and expects to leverage its surgical valve footprint. The article also notes FDA Breakthrough designation for Aidoc’s AI and OTC Dexcom Stelo clearance for children.

Edwards Lifesciences (EW) reported Q2 2026 sales up 12.5%, driven by structural heart growth across TAVR and TMTT. Management raised full-year 2026 sales guidance to 10% to 11% and expects TMTT revenue to reach $2B by 2030. Key catalysts include U.S. TAVR NCD in September and PROGRESS trial results later in 2026.

Edwards Lifesciences reported Q2 2026 sales of $1.74 billion and 12.5% underlying growth, with adjusted EPS of $0.78. After results beat expectations, it raised full-year 2026 sales growth to 10% to 11% and net sales guidance to $6.6 billion to $6.9 billion. TAVR Q2 sales were $1.3 billion, up 10.5% YoY.